Mortality rates are elevated in people with multiple sclerosis (MS) relative to the general population. There is, however, some uncertainty whether suicide contributes to this. Epidemiological data suggest that the standardized mortality ratio (SMR) for suicide in MS is approximately twice that of the general population with younger males in the first few years following diagnosis most at risk. Rates of suicidal intent, a potential harbinger of more self-destructive behavior, are also elevated, but the frequency with which intent is followed by suicide is not known. Depression, severity of depression, social isolation, and alcohol abuse are associated with thoughts of suicide. The variables linked with suicide and suicidal intent are therefore well defined and should be readily available from routine clinical inquiry. While vigilance on the part of clinicians is required, particularly in the context of high-risk patients, it is also recognized that prevention is dependent on full disclosure of intent.
"Killing oneself is, anyway, a misnomer. We don't kill ourselves. We are simply defeated by the long, hard struggle to stay alive. When somebody dies after a long illness, people are apt to say, with a note of approval, 'He fought so hard'. And they are inclined to think, about a suicide, that no fight was involved, that somebody simply gave up. This is quite wrong." 1 There is no more emotive topic in medicine than suicide. In an age of evidence-based medicine in which outcomes are scrutinized, mulled over, fiercely debated, and disagreed upon, suicide stands apart. Here, there is unanimity-it is the outcome no-one wanted, not even the deceased, we reason, for surely such an extreme behavior is the product of a disordered mind with judgment overcome by pain, depression, and despair. This topical review on suicide will not touch on the philosophical discourse that surrounds the logic and morality of a person taking his or her life. Readers wanting an introduction to this aspect of suicide are instead referred to Simon Critchley's recent, erudite monograph, "Notes on Suicide." 2 The subject of physician-assisted suicide will also not be addressed given the complexity of a subject which demands a separate topical review to itself. Instead, the focus will be on quarter century of multiple sclerosis (MS) literature which has explored, with varying results, the key question of whether rates of completed suicide are elevated in people with MS. In addition, the literature pertaining to putative risk factors for suicide will be critically reviewed together with the topic of suicidal intent, a potential harbinger of more ominous behavior to come.
Frequency of suicide relative to the general population
The preferred method for determining whether rates of suicide are elevated is the standardized mortality ratio (SMR). This refers to the ratio of the observed number of deaths in people with MS over a given period to the number of deaths expected in the general population during the same period. SMR factors in an age correction, an important consideration in assessing suicide given that the rate within the general population is highest in middle age with a second peak in the very elderly. 3 SMRs also allow for the provision of confidence intervals (CIs) and significance values, which will be reported in this review where available. An SMR of greater than 1.0 indicates an increased suicide rate in the population studied, but does not necessarily imply statistical significance. Some studies report significance, whereas others prefer CIs. These different approaches complicate direct study comparisons.
Many of the epidemiological findings relating to suicide in people with MS come from Scandinavian countries given their extensive population-based databases. In those studies which revealed elevated SMRs, the findings are generally consistent. A Finnish study of 1595 people with MS diagnosed between 1964 and 1993 reported a 1.7 SMR (95% CI: 0.9-2.7). 4 Three Danish studies reached similar conclusions. In the first of these, 5525 subjects who had been diagnosed with MS between 1953 and 1985 were identified from the Danish Multiple Sclerosis Registry (DMSR). 5 Of this onset cohort, 53 were known to have committed suicide during this period. A comparison with population-based data adjusted for duration of observation, age, sex, and the calendar year at the start of the period of observation gave an SMR of 1.83 (95% CI: 1.37-2.40). A second study using the DMSR revealed that 3360 people with MS had died during the period 1951-1993 giving an SMR for suicide of 1.62 (95% CI: 1.29-2.01). 6 The final DMSR study investigated the suicide rate in people with MS diagnosed between 1953 and 1996. 7 The end of the follow-up period was 1 January 1999. During this 46-year period, 115 people with MS (63 men, 52 women) had taken their own lives, significantly higher than the predicted 54.2 people based on adjusted population norms. This gave an SMR of 2.12 (95% CI: 1.75-2.55). These findings overlap with a Swedish hospital-based study that covers the period 1969 through 1996 during which time 12,834 people were admitted and given a discharge diagnosis of MS. During a 9.9-year (standard deviation (SD) = 7.3) follow-up period, 90 (1.8%) individuals died by suicide giving an SMR of 2.3 (95% CI: 1.85-2.83). 8 A second Swedish study did not calculate an SMR but instead reported a hazard ratio (HR) estimated from a Cox regression analysis which adjusted for timeline and demographics. 9 The findings, however, were similar for completed suicide with an HR of 1.87 (95% CI: 1.53-2.30). Finally, there is one Canadian study, often cited, which concluded that rates of suicide in people with MS were 7.5 times than that in the general population. 10 This markedly elevated rate, a statistical outlier, reflects a faulty methodology and will not be discussed further.
A closer look at the above studies is informative. While the similar SMRs in the three Danish studies is not surprising given they all used data from the same registry and only differed slightly in the time period covered, it is notable that the Finnish and Swedish results matched the Danish data. One study reported that suicide risk was highest in the first year after diagnosis (SMR = 3.15), 7 whereas others found that the high-risk period extended to 5 years post diagnosis. 4, 8, 11 Additional risk factors identified were males with an onset of MS before 30 years of age. 5 As in the general population, women were found to attempt suicide more often than men, but men were more likely to succeed with their attempt. 9 These findings of an elevated suicide rate are offset by other studies that reported different results. A study investigating trends in MS mortality rates in the United States between 1990 and 2001 looked at age, sex, and ethnicity-adjusted MS mortality rates in comparison with randomly selected deaths from other conditions. 12 The matched odds ratio (OR) of suicide being reported as a cause of death was 0.17 (95% CI: 0.15-0.20). A Manitoba study identified all people in the province who had died by suicide between 1996 and 2009 and through a complicated process of matching each deceased person to three living control subjects compared unadjusted and adjusted (age, mental illness comorbidities, income) ORs for MS. 13 While the unadjusted OR of 2.54 (95% CI: 1.14-5.67) was found to be significant, the adjusted OR of 1.97 (95% CI: 0.75-5.13) was not. A cohort study used prospectively collected data from the United Kingdom General Practice Research Database, which includes anonymized computerized medical records of approximately 6% of the UK population at any one time. 14 All prevalent cases of MS between two time periods, 1993-2000 and 2001-2006 were identified (n = 1822) with each person randomly matched to up to 10 subjects without MS. All subjects were followed until death or the date of the last data collection. While the all-cause mortality rate was found to be increased in the MS group, this did not include suicide. Finally, there is a constellation of studies with a miscellany of methodologies in which suicide rates are combined with rates of accidental death, thereby obscuring any meaningful suicide data extraction. [15] [16] [17] [18] A comparison of studies showing an elevated risk of completed suicide with those that do not reveal that the former are generally the product of a uniform methodology (predominantly SMR based) whereas the latter reflect a variety of approaches. Where there are negative SMR data, as in a Norwegian study confined to residents of Oslo with onset of MS between 1940 and 1980, the unfortunate lumping together of death by suicide and accident hinders interpretation. 18 Adding to the challenge, at least one study reported an elevated SMR as non-significant. 4 However, it is notable that a recent meta-analysis incorporating MEDLINE, Embase, and Cochrane Library databases and restricted to SMR data concluded that death due to suicide is higher in people with MS than in the general population. 19 Two reviews with different methodologies arrived at the same conclusion. 20, 21 
Suicidal attempts and intent
A study of people with MS hospitalized between 1992-1993 and 1994-1995 in the Canadian province of Nova Scotia revealed the prevalence of bipolar affective disorder and depression to be 1.97% and 4.27%, respectively, twice as high as in the general population of hospitalized patients. 22 Suicide attempts, while rare, were three times more frequent in the MS group.
Two studies have used the Patient Health Questionnaire (PHQ-9), a nine-item psychometric scale that mirrors the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM5) symptom checklist for major depression, to assess suicidal intent in people with MS. During a 2-week period, 8.5% of 188 people with MS endorsed suicidal thoughts, and this rose to 22.1% over the course of 6 months. 23 Factors associated with suicidal thinking, once the effects of depression had been controlled for, were age over 65 years, maladaptive coping strategies, and more marked physical difficulties with bladder, bowel swallowing, and speech. The results from a second PHQ-9-based study of 445 people with MS reported a more than threefold higher prevalence of transient suicidal thoughts (29.4%) over a 2-week period which were linked to younger age, progressive disease course, higher levels of disability (once again bladder and bowel symptoms featuring prominently), single marital status, lower income, not being able to drive, and depression. 24 A logistic regression, however, pared down these independent predictors to depression and disabling bowel symptoms. When the focus shifted to persistent suicidal thinking, the prevalence dropped to 10.8% with depression as the sole predictor. A German survey of 867 people with MS employed a different methodology by asking participants a single question-"How often do you think about ending your life?"-scored on a 5-point Likert scale ranging from "never" to "all the time." 25 A detailed psychosocial inquiry was completed too as part of this postal survey and revealed that 22.1% of participants endorsed thinking about suicide "often," "very often," or "all the time." Depression, reduced leisure activities secondary to MS, and feeling excluded were all significantly associated with feeling suicidal, whereas having a sense of purpose in life, being productive, and strong spiritual beliefs were found to be protective in this regard. While these results point to factors that can in theory be modified as a way of reducing thoughts of self harm, the study's methodology suggests a note of caution when interpreting the results, no matter their good face validity. In particular, responses were obtained from people with MS responding to an advertisement placed in the journal Aktiv of the German MS Society, an approach which will have introduced a bias.
The absence of good, supportive social bonds (endorsed as "loneliness") emerged once more as a significant correlate of suicidal thinking in a study of 16 people with MS that employed a qualitative rather that quantitative methodology. 26 The gist of this detailed inquiry was the central role played by perceived loss of control in generating thoughts of suicide. Within this umbrella term could be found numerous examples of how people with MS attribute their diminished role across multiple domains to the effects of the disease. Finally, in a study of 140 consecutive MS clinic attendees that incorporated detailed structured interviews to elicit psychopathology, lifetime suicidal intent was found in 28.6% of participants. 27 This in turn was associated with lifetime diagnoses of major depression, anxiety disorder, co-morbid depression-anxiety disorder, alcohol abuse, a family history of mental illness, and living alone. Three potentially modifiable variables, namely, severity of major depression, living alone, and alcohol abuse, had an 85% predictive accuracy for suicidal intent. Just as tellingly, a third of suicidal individuals had received no psychological help while two-thirds of participants with a major depression, all suicidal, were not receiving therapy.
Risk factors
Collecting suicide data is by its very nature retrospective and may be incomplete depending on the accuracy of ascertaining the cause of death. There is nevertheless sufficient evidence suggesting that younger males within the first 5 years of their MS diagnosis are particularly vulnerable. Suicidal intent in turn is robustly associated with depression and social isolation. While the frequency with which intent is followed by suicide is not known, these demographic and illness-related risk factors should be familiar to all health care professionals involved in treating people with MS. The need for vigilance is reinforced by a high lifetime prevalence rate of major depression in MS. 28
Interferon β and suicide
Concerns that suicide might be linked to treatment with a disease-modifying agent emerged in the first interferon β-1b trial of people with relapsing-remitting MS. 29 One completed suicide and suicide attempts were documented in both treatment arms (1.6 and 8 million international units (MIU)), but none in the placebo group. Subsequent studies have not replicated the result, 30, 31 and a thorough review of the MS interferon β-1a and β-1b literature has concluded that treatment per se does not carry a greater risk of attempted self harm or suicidal intent. 32 In retrospect, the failure of the initial interferon β-1b study to record details of a premorbid and family history of mental illness hindered data interpretation for there is now robust evidence that depression prior to the onset of treatment, in particular, is associated with depression once treatment has started. 33 Clinical practice therefore dictates that depression is not a contraindication to treatment, but that all patients in treatment should nevertheless be monitored carefully for signs of an emergent mood disturbance that might include suicidal thinking.
Summary
Current research reveals two main points that deserve attention, but which falter when confronted by a caveat. First, suicide rates in people with MS are elevated with SMR data indicating an approximate twofold increase relative to the general population. Second, there are readily attainable clinical data that suggest where efforts should focus in reducing risk. Here, traditional pathways to care means detection begins with the neurologist or clinic nurse, with a speedy referral to a psychiatrist or psychologist to follow.
Those who work at this interface know, however, that knowledge and access to care are not always enough. I recall a person with MS and bipolar disorder who saw me in the morning and his neurologist that afternoon. We both documented, independently, how well he appeared. All the right questions were asked and answered. No alarm bells sounded. His mood appeared stable and his MS in remission. That evening he killed himself. From his suicide note, we learned that he had been planning it for weeks. Tragic vignettes like this are not uncommon. "For what man knoweth the things of a man, save the spirit of man which is in him?" asks the Book of Corinthians. 34 This hard truth lays bare what can be an insuperable hurdle, one which defeats not only the most careful inquiry, but ultimately the patient too.
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